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Abstract
Significant advances in our understanding of the
biology of renal cell carcinoma (RCC) have been
achieved in recent years. These insights have led to
the introduction of novel targeted therapies,
revolutionising the management of patients with
advanced disease. Nevertheless, there are still no
biomarkers in routine clinical use in RCC. Tools used
routinely to determine prognosis have not changed
over the past decade; classification remains largely
morphology based; and patients continue to be
exposed to potentially toxic therapy with no
indication of the likelihood of response. Thus the
need for biomarkers in RCC is urgent. Here, we focus
on recent advances in our understanding of the
genetics and epigenetics of RCC, and the potential for
such knowledge to provide novel markers and
therapeutic targets. We highlight on-going research
that is likely to deliver further candidate markers as
well as generating large, well-annotated sample banks
that will facilitate future studies. It is imperative that
promising candidates are validated using these
resources, and in subsequent prospective clinical trials,
so that future biomarkers may be used in the clinic to
personalize patient care.
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Renal cell carcinoma
Renal cancer is the eighth most common cancer in the
UK. There are over 270,000 new cases worldwide each
year, 9,000 of which occur in the UK [1,2]. It accounts
for more than 100,000 deaths across the world per
annum [2]. The vast majority (approximately 90%) of
renal cancers arise in the renal parenchyma and are
termed renal cell carcinomas (RCC). The incidence of
RCC has been steadily rising over the past 20 years in
many countries and this is thought to be only partially
explained by the increased rate of incidental diagnosis.
The most common histological subtype of RCC is the
conventional or clear cell (ccRCC) type accounting for
70% to 80% of cases. Central to the biology of ccRCCs,
which form the focus of this review, is loss of function of
the Von Hippel-Lindau (VHL) tumour suppressor gene
(TSG), located on chromosome 3p. More than 90% of
sporadic ccRCCs have VHL involvement, almost defining
this subgroup of tumours [3,4]. Loss of function of the
VHL protein leads to stabilisation of hypoxia-inducible
factors, nuclear transcription factors that in turn can acti-
vate the transcription of many genes including those
encoding vascular endothelial growth factor (VEGF) and
platelet derived growth factor.
The majority (60% to 70%) of patients present with
localised disease, for which radical or partial nephrect-
omy remains the standard of care and is largely curative.
However, approximately one third of these patients will
subsequently relapse and die of their disease. Accurately
determining the risk of relapse after nephrectomy is a
key issue for patients and clinicians. This would not only
inform and personalize imaging and follow-up schedules
but also determine the risk:benefit ratio for adjuvant
therapy, if on-going trials are positive. Current nomo-
grams used to determine risk are still based on clinico-
pathological criteria only, and were developed more than
a decade ago [5]. Such scoring systems are reasonably
accurate at a population level but distinguishing risk for
individuals, particularly those deemed at intermediate
risk, remains poor. This is a key area where biomarkers
are urgently required in RCC.
Insights into the biology of ccRCC have directly led to
the recent introduction of a number of effective systemic
therapies (see Figure 1). Antiangiogenic VEGF receptor
(VEGFR)-targeted tyrosine kinase inhibitors (TKI), such as
sunitinib and pazopanib, are established as front-line ther-
apy for patients with advanced RCC. However, the clinical
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benefit an individual patient will derive from such therapy
is highly variable and largely unpredictable. Between 20%
and 30% of patients with ccRCC derive no benefit from
first-line TKI treatment [6,7]. In addition, these drugs are
toxic and expensive. Modern medical practice demands
value for money. There is thus great impetus to discover
biomarkers in RCC that can identify the subpopulation of
patients destined to gain maximal benefit from any given
drug. Numerous studies, variably examining clinicopatho-
logical criteria, VHL status, serum cytokines and angio-
genic factors in relation to TKI response have been
published, and reviewed elsewhere [8].
Despite the tremendous spectrum of behaviour that
characterises ccRCCs, the current approach to the man-
agement of patients with these tumours remains largely
generic. Robust and clinically validated biomarkers are
required if the long-held promise of personalized medi-
cine is to be realised. In this review, we summarise
some of the most recent and promising areas of genetic
and epigenetic biomarker research in ccRCC. We also
highlight a number of large biomarker initiatives in RCC
that are underway and, finally, we discuss some of the
issues related to successfully bringing RCC biomarkers
into the clinic. A detailed review of protein biomarkers
of RCC and the potential of proteomics strategies in this
area is beyond the scope of the current review and has
been covered elsewhere by the authors [9]. In addition,
although the current focus is on ccRCC, much greater
research is also urgently required into the other, less
common, subtypes of RCC, to define the biology of
these tumours and lead to rational therapeutic design.
Recent advances in genetic, epigenetic and
transcriptomic understanding of clear cell renal
cell carcinoma
Tremendous progress has been made in recent years in
terms of our understanding of the genetic basis of can-
cer. In particular, the advent of second-generation DNA
Figure 1 Biological pathways targeted for therapy in renal cell carcinoma based on a knowledge of the underlying genetic changes and
downstream biological consequences. Loss of function of the VHL tumour suppressor gene leads to stabilisation of hypoxia-inducible factor
alpha (HIFa). Activated HIF translocates into the nucleus and leads to the transcription of a large number of hypoxia-inducible genes including
vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF). Mammalian target of rapamycin (mTOR) is a kinase within the
PI3K/Akt pathway that can promote cell growth and survival pathways as well as causing accumulation of HIF. Bevacizumab is a monoclonal
antibody to VEGF whilst sunitinib, sorafenib, axitinib and pazopanib are VEGF receptor tyrosine kinase inhibitors. These agents are thought to
primarily function as antiangiogenic agents, inhibiting ligand binding or downstream receptor signalling of VEGF and PDGF on endothelial cells.
Temsirolimus and everolimus inhibit the kinase activity of the mTOR complex 1 (mTORC1). Reproduced with permission from Elsevier©. From [66].
HIF: hypoxia-inducible factor; mTOR: mammalian target of rapamycin; mTORC1: mTOR complex 1; PDGF: platelet derived growth factor; PTEN:
phosphatase and tensin homolog; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor.
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sequencing technology is allowing researchers to start to
systematically catalogue the thousands of somatic muta-
tions that can typically be found in adult cancers and it
is expected that tens of thousands of cancer genomes
will be sequenced in the next 5 years [10]. This is,
therefore, a time of great anticipation and it is expected
that studies at genetic, epigenetic and transcriptomic
levels will together identify the full complement of key
driver mutations and epigenetic contributions across all
cancer types, including RCC [11]. Complemented by
information obtained at the level of the proteome [12],
it is expected that these studies will together ultimately
result in the identification of novel biomarkers and ther-
apeutic targets of cancer.
DNA
Amongst the most notable genetic abnormalities asso-
ciated with ccRCCs are loss of chromosome 3p (70% to
80%) and gain of chromosome 5q (50% to 60%) [13].
Loss-of-function mutations in the remaining VHL allele
are thought to represent an early event in ccRCC devel-
opment but are not sufficient alone to drive tumour
growth. A second major TSG recently implicated in
ccRCC is the SW1/SNF chromatin remodelling complex
gene polybromo1 (PBRM1), with truncating mutations
found in 41% of the 227 cases tested [14]. Other genes,
such as SET domain containing protein 2 and Jumonji
AT-rich interactive domain 1C have also been impli-
cated, although at much lower frequency (3%) [15].
More recently, mutations in BRCA related protein-1
(BAP1) have been reported, with inactivation of BAP1
protein in 15% of ccRCCs. Interestingly, mutations in
PBRM1 and BAP1 were largely observed to occur exclu-
sively, suggesting that simultaneous loss may be disad-
vantageous to the tumour [16]. In comparison with the
PBRM1 mutation, BAP1-deficient tumours were of
higher grade and had distinct gene expression profiles.
Distinguishing these genetically distinct subgroups may,
therefore, have important prognostic and therapeutic
implications for individual patients. It is of note that
this may be achievable at the protein level, examining
BAP1 protein expression by immunohistochemistry, for
example, which is less expensive, has a higher through-
put and is more routinely available [16].
The real message from these studies is perhaps that
even relatively large-scale analyses may be underpow-
ered to capture the full spectrum of mutations that
drive these tumours and must be differentiated from the
many bystanders. There is, therefore, a need for even
larger studies, ultimately including thousands, rather
than hundreds, of samples and covering whole genomes
so that potentially important non-exomic changes can
also be identified. Such studies are in fact underway (see
later) and are required if further significant insights,
beyond VHL, PBRM1 and BAP1, are to be gained.
Gene expression microarrays
Gene expression microarrays represent a promising
method by which to subclassify tumours, both across
subtypes and within clear cell carcinomas. Importantly,
of course, they encompass both upstream genetic and
epigenetic changes. Such approaches may also provide
prognostic information that can be implemented in daily
clinical practice. A proof of concept has been established
in other tumour types, such as breast cancer: Mamma-
Print is a Food and Drug Administration approved 70-
gene signature, stratifying tumours as high or low risk,
which has been widely adopted into clinical practice in
countries such as the USA. Studies to date in ccRCC
have established that these tumours can also be strati-
fied based on gene expression profiling, and that this
may provide information independent of stage and
grade [17-20]. However, these studies have typically
been small, with limited numbers of genes analysed, and
not independently validated. Indeed, in a recently pub-
lished meta-analysis of gene-expression studies in
ccRCC, just six studies were included after excluding
those with fewer than 20 tumours, those with fewer
than 5,000 genes analysed, those containing no clinical
data and redundant publications of previous data [21].
The meta-array assembled gene expression data from
480 tumours, encompassing 6,386 genes. Based on pre-
vious work by the same authors, the study demonstrated
the ability of such profiling to segregate ccRCCs into
two distinct subtypes, termed ccA and ccB. ccA tumours
relatively overexpressed genes associated with hypoxia,
angiogenesis and fatty acid metabolism and carried a
favourable prognosis in comparison with ccB tumours,
which overexpressed a more aggressive panel of genes
associated with epithelial-mesenchymal transition, cell
cycle and wound healing. Interestingly, rates of VHL
involvement were similar between the two groups [18].
A third, small (14%) cluster of tumours could also be
identified, 82% of which were classed as VHL wild-type.
Importantly, a histological review of these cases demon-
strated that over half displayed deviations from classical
clear cell features, suggesting that such tumours may
warrant distinct classification.
Another recent study combined copy number analysis
with gene expression analysis to identify potential novel
subtypes and therapeutic targets in ccRCC. The study
examined 54 cases of sporadic ccRCC, and found 350
concordantly gained and overexpressed genes. Gain in
chromosome 5q was observed in 30% of cases, and stan-
niocalcin (STC2) and versican (VCAN) were identified as
potential oncogenes in ccRCCs, which appear to act by
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inhibiting cell death [22]. The study is notable for
describing gain-of-function aberrations, rather than the
more commonly described loss of function in tumour
suppressors; these gain-of-function aberrations may
represent more direct therapeutic targets
Histopathological classification of RCC can prove
challenging in some cases [23,24]. The ability to differ-
entiate between subtypes is important, because prog-
nosis and treatment can vary, and there are implications
for clinical trial recruitment. Gene expression signatures,
using as few as 10 genes, have shown more than 90%
accuracy in distinguishing between clear cell, papillary
and chromophobe RCCs as well as benign oncocytomas
[25]. Such profiling may prove to be of value in the
clinic if shown to have the ability to subtype currently
unclassifiable tumours, or in cases that are otherwise
difficult to distinguish (for example, eosinophilic
tumours). In addition, the increasing interest in neoad-
juvant therapy means that pathologists are required to
make initial diagnoses on much more limited amounts
of tissue, derived from core biopsies alone, where
expression profiling may also prove useful.
Single nucleotide polymorphisms
Large genome-wide association studies have recently
reported SNPs that may increase the risk of an indivi-
dual developing RCC [26,27]. Such genetic variation
within our germline, in addition to somatic mutations
within tumours, may also help to explain observed dif-
ferences in response and toxicity to anticancer agents.
A number of SNP-based studies in RCC addressing
the response to TKI therapy have recently been pub-
lished. In the largest study of 397 patients treated with
pazopanib, 27 polymorphisms amongst 13 genes, includ-
ing those related to angiogenesis (VEGFA/IL-8/fibroblast
growth factor 2), metabolism (cytochrome P450 (CYP)
3A4/5)}) and transport (ATP-binding cassette (ABC) B1)
were evaluated. Two IL-8 polymorphisms, linked to
increased gene expression, were associated with a signif-
icantly shorter median PFS (27 weeks) than those carry-
ing the wild-type genotype (48 weeks) (P = 0.01) [28]. It
is of note that IL-8 has recently been identified as a
potential driver of resistance to TKIs [29], making the
results of biological relevance. A second study, con-
ducted prospectively, examined both response (n = 89)
and toxicity (n = 95) to sunitinib in patients with
ccRCC. A total of 16 polymorphisms were examined in
nine genes. Two VEGFR3 missense polymorphisms were
associated with reduced PFS and a high metabolising
variant of CYP3A5*1 was associated with increased toxi-
city on multivariable analysis. However, the reported
SNPs involving IL-8 were not demonstrated in this
study [30]. In a retrospective study of 136 patients with
metastatic ccRCC treated with sunitinib, 30 SNPs in 11
genes were examined, and correlated with PFS. Survival
was significantly improved in relation to SNPs in
CYP3A5, ligand-activated nuclear receptor NR1I3 and
ABCB1, but not in VEGFR3 [31].
Thus, studies to date in this area show little concor-
dance. The frequency of the reported SNPs in the tested
populations was typically low, highlighting the need for
such studies to be much larger to increase their power
to detect significant differences. Furthermore, the applic-
ability of the results to populations of differing ethnicity
is also unknown.
DNA methylation
DNA methylation represents the best characterised
mechanism by which cancer cells can epigenetically regu-
late gene expression. Methylation of cytosine residues
within CpG dinucleotides can alter the transcription rate
of a given gene and bring about transcriptional silencing.
Cancer cells often demonstrate TSG inactivation as a
result of aberrant promoter hypermethylation [32].
In sporadic ccRCC, the VHL TSG is inactivated via
methylation in approximately 10% to 30% of cases
[3,4,33]. Methylation studies, including recent genome-
wide based approaches, have now identified a large
number of other candidate TSGs inactivated by hyper-
methylation in ccRCC, which, in many cases, occur at
high frequency within the studied sample sets [34,35].
The Ras association domain family 1 gene, for example,
codes for a protein that functions as a negative regulator
of the cell cycle and is methylated in approximately 45%
of cases [33]. Secreted frizzled related protein 1, which
antagonises Wnt signalling, is methylated in 34% to 68%
of ccRCC tumours [36,37]. Many other examples exist,
as recently reviewed [38].
Such studies clearly provide further insights into the
biology of ccRCC but can markers of methylation also
serve as novel biomarkers in the clinic? Correlations
between methylation status and patient outcome have
been reported although none have been validated.
Methylation of gremlin1, a protein that antagonises
growth factor signalling, has been correlated with a
poorer overall survival in patients with ccRCC. The
study included 185 patients, 40% of whom had methyla-
tion of the gremlin1 gene [39]. Methylation of GATA-
binding protein 5 has recently been correlated with the
development of metastasis (P = 0.005) and decreased
progression-free survival (P = 0.005, hazard ratio = 4.59)
in 84 patients with ccRCC [40]. In another study of 69
patients with ccRCC, in the 19% of patients with methy-
lation of signal peptide CUB EGF-like domain-contain-
ing protein 3, risk of cancer death or relapse was
significantly increased (P = 0.0046) [35].
Intriguing data have recently been published from stu-
dies in bladder cancer, another urological malignancy,
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suggesting that urinary methylation markers may be
used to diagnose bladder cancer [41]. Furthermore, such
markers may also predict the progression of early blad-
der lesions to muscle-invasive tumours with a high
degree of accuracy [42]. It is also possible that urinary
DNA methylation markers may be used in RCC to allow
early detection of disease, potentially using a pan-urolo-
gical panel of markers [43].
microRNA
miRNAs are single-stranded, non-coding RNAs approxi-
mately 22 nucleotides long that are emerging as a
potentially important and novel source of epigenetic
biomarkers in RCC. miRNAs function by regulating
gene expression at a post-transcriptional level, binding
to target mRNA, typically resulting in translational
downregulation, inhibition and/or mRNA degradation
but also, more rarely, upregulation. miRNAs are altered
in many cancers, including RCC, and can affect many
tumourigenic pathways including cell cycle regulation,
proliferation, cell motility, metastasis, apoptosis and
angiogenesis.
Many alterations in the expression of miRNAs in RCC
have been described to date (for reviews see [44,45])
and provide fresh insight into the aetiology and biology
of these tumours. miR210, for example, has consistently
been reported to be upregulated in ccRCC in response
to hypoxia, and promotes anaerobic respiration and cell
cycle progression and inhibits pro-apoptotic signalling
[46-48]. Furthermore, expression of miR210 has been
correlated with a significantly poorer overall survival (P
= 0.0006), even among a small number of patients (n =
31) [49].
miRNA-based signatures may also allow for improved
classification of tumour subtypes. In a recent study of 94
fresh frozen samples, composed of normal renal epithe-
lium and clear cell, papillary and chromophobe RCC sub-
types as well as oncocytomas, 91 miRNAs were found to
be significantly differentially expressed. Clear cell
tumours were shown to be more closely related to papil-
lary RCC and both were distinct from chromophobe and
oncocytomas, which were more closely related. Tumours
could be classified using unique miRNA signatures in a
maximum of four steps. The system had a sensitivity of
97% in distinguishing normal from RCC, 100% for clear
cell RCC, 97% for papillary subtype and 100% accuracy in
distinguishing oncocytoma from chromophobe tumours.
This latter distinction is notoriously difficult based on
morphology alone [50].
It is worth noting that miRNAs are stable and can in
fact be reliably measured in formalin-fixed paraffin-
embedded material. Furthermore, as recent studies have
shown, miRNAs can also be measured in serum and
serve as potential diagnostic markers of disease [51,52].
Finally, and perhaps most exciting, miRNAs may serve
as novel therapeutic targets. Because any given miRNA
may target hundreds to thousands of genes, such an
approach may have the capacity to ‘hit’ several pathways
simultaneously. However, at present, such an approach
remains in its infancy across all cancer types, not just in
RCC.
Current renal cell carcinoma biomarker initiatives
A number of large-scale biomarker initiatives are under-
way in RCC, some of which are described below.
CAGEKID
The Cancer Genomics of the Kidney (CAGEKID) con-
sortium [53], funded by the European Union (EU) (total
€10 million), aims to carry out comprehensive genetic,
epigenetic and transcriptomic analysis in ccRCC. Exten-
sive characterisation of 100 patients and two phases of
targeted validation in a further 400 and 2,300 patients
will be performed. The study forms part of the Interna-
tional Cancer Genome Consortium initiative [11] and,
as such, all samples entered are subject to pathology
panel review and minimum standards used in terms of
viable tumour cell number. The consortium is com-
posed of 14 partners from 6 EU countries (plus Russia),
including the Czech Republic. A schema for the CAGE-
KID study is shown in Figure 2. The study is currently
in its initial validation phase.
Evaluation of biomarkers in patients with renal cell
carcinoma
As part of a National Institute for Health Research
funded programme (’Biomarker pipeline’), tissue and
fluid samples from patients with RCC are being col-
lected at 10 UK centres, with a target of 600 patients at
baseline, longitudinal sampling in a further 200 patients
and long-term follow-up in all. Samples are being col-
lected according to strict standard operating procedures,
together with clinical data via case report forms. An
important remit of the study is the careful evaluation of
existing and future putative prognostic and longitudinal
monitoring protein biomarkers for use in the clinic,
incorporating validation of developed and existing
assays. The sample bank will also be available for future
gene and protein studies [54].
EuroTARGET
EuroTARGET (TArgeted therapy in Renal cell cancer:
GEnetic and Tumour related biomarkers for response
and toxicity) is another European collaboration, com-
posed of 12 partner organisations from 8 countries,
funded by the European Commission under the Seventh
Framework Programme. The aim of the study is to iden-
tify predictive biomarkers of response and toxicity to
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targeted therapy in patients with RCC using approaches
that include germline genome analysis and tumour gene
expression and methylation studies [55].
SCOTRRCC
The Scottish Collaboration on Translational Research
into RCC (SCOTRRCC) is a Scotland-wide initiative
involving 10 centres, aimed at banking clinical samples
from newly diagnosed patients with RCC to address var-
ious clinical and scientific research questions. Samples
will be collected, processed and stored in a robust and
uniform manner, accompanied by comprehensive clinical
annotation, providing a further highly valuable biobank.
PREDICT Consortium
personalized RNA Interference to Enhance the Delivery
of Individualised Cytotoxic and Targeted therapeutics
(PREDICT) is a European collaboration aimed at identi-
fying predictive biomarkers of response to sunitinib and
everolimus in patients with RCC [56]. Patients within
the study provide consent to receive neoadjuvant ther-
apy, allowing the collection and comparison of tissue
both before and after exposure to the drug. Tumours
will be comprehensively genomically profiled and high-
throughput screens using short hairpin RNA and small
interfering RNA will be used to identify and validate
functionally important genomic or transcriptomic pre-
dictive biomarkers of individual drug response in
patients.
TCGA
The Tumour Cancer Genome Atlas (TCGA) is a US
initiative funded by the National Institutes of Health
that sets out to comprehensively genomically profile 20
Figure 2 Cancer Genomics of the Kidney (CAGEKID) study schema. RCC: renal cell carcinoma.
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different tumour types, including both ccRCC and papil-
lary RCC. The study has already banked its target of 500
ccRCC samples, and aims to conduct whole genome
sequencing in 50 of these cases. As with other initia-
tives, the data will be made available to the scientific
community [57].
The future of using biomarkers for personalized
medicine for renal cancer
Treatment options and outlook for patients with renal
cancer have seen significant improvement in recent years:
surgical techniques have improved; tumour-ablative proce-
dures are more widely available; and effective targeted
agents have been discovered. But what next? Further
major advances are likely to require the introduction of
biomarkers into clinical practice to personalize patient
care.
An abundance of potential candidate RCC biomarkers
exist in the literature, yet none have progressed beyond
the discovery phase, an issue that has plagued biomarker
research across all cancer types [58]. Some of the most
promising markers in RCC are in fact proteins, such as
B7-H1 and insulin-like growth factor II mRNA binding
protein 3, that have been shown in RCC to have strong,
independent prognostic ability, have been externally vali-
dated and add value to existing nomograms [59,60], yet
appear to have stalled at this point in the ‘biomarker pipe-
line’ (Figure 3). Even C-reactive protein, a more routine
and easily measured marker, has not been evaluated
further, despite having been shown in multiple studies to
be of prognostic value and occur not just as an inflamma-
tory marker but be produced by RCC cells [61]. If genomic
markers are not to similarly stall in their development, it is
important that these issues are urgently addressed. As
others have argued [62], to date, too much emphasis has
been placed on the discovery phase of biomarker research
and not enough on validation and integration of markers
into clinical care. Thus, alongside current discovery initia-
tives, a priority in RCC biomarker research must be to
validate, in or out, existing promising markers, following
robust assay development.
Can biomarkers be successfully integrated into clinical
practice in RCC? It is certainly appealing to envisage a
future in which patient management is influenced by
molecular information that can be reliably provided in
‘real-time’. Thus, from a single renal biopsy, a wealth of
information would be gleaned at both a genetic and pro-
tein level, defining the tumour more so on its molecular
profile than its site of origin. Based on this notion,
initiatives such as Cancer Research UK’s Stratified Medi-
cines Programme are already exploring how the
National Health Service can provide molecular profiling
routinely for all cancer types and lay the foundations for
a national service that can deliver standardised, high
quality, cost-effective genetic testing of tumours [63].
Among the many issues relating to the successful
introduction of individualised cancer care, perhaps one
the greatest challenges comes from the increasing recog-
nition that individual tumours, across many cancer
types, are themselves highly heterogeneous [64]. The
remarkable degree of heterogeneity that exists within
individual ccRCCs has recently been elegantly demon-
strated [65]. Using multi-region genetic analysis, this
study showed that the majority (approximately two
thirds) of mutations are not present in every region of a
tumour, and that a single biopsy would capture only a
minority of the genetic aberrations present. Further-
more, different areas of the same tumour variably
returned either a favourable or unfavourable prognostic
profile, using the gene expression array described above
[18], suggesting possible diversity amongst biologically
relevant (driver) mutations.
Such heterogeneity of course is a feature of all cancers
and potentially carries significant implications for
Figure 3 Biomarker pipeline. Biomarkers must be carefully evaluated along each phase of the pipeline for successful adoption into clinical
practice.
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successful biomarker validation and the delivery of per-
sonalized care [64]. A single biopsy may not be repre-
sentative of the tumour as a whole and even multiple
sampling post-nephrectomy may be inadequate. A
further level of complexity is also added by the fact that
the signature of the primary tumour may not necessarily
reflect that of distant metastatic deposits [65]. What
remains uncertain, however, is the extent to which these
differences actually impact on the tumour phenotype
and, for instance, the expression of protein biomarkers
and therapeutic targets. For now, the key message is
that heterogeneity exists and must be considered along
the route to successful biomarker validation.
Conclusions
This is a highly promising time in the field of RCC bio-
marker research. The advent of high-throughput molecu-
lar profiling technologies is leading to a revolution in our
understanding of the biology and make-up of RCC and,
in parallel, a number of large-scale, collaborative biomar-
ker discovery initiatives are underway. It is expected that
these studies, complemented by proteomic initiatives,
will identify further novel candidate biomarkers of RCC.
Equal efforts must then be applied to the clinical valida-
tion phase for such studies to be rendered worthwhile.
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